The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142.
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; ALX Oncology; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Taiho Pharmaceutical; Takeda; TERUMO; Zymeworks
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
M. Luisa Limon
No Relationships to Disclose
 
Mark Ka Wong
Consulting or Advisory Role - MSD Oncology
Speakers' Bureau - MSD Oncology; Sirtex Medical
 
Alain Hendlisz
Consulting or Advisory Role - Bayer (Inst); MSD Oncology (Inst); Sirtex Medical (Inst)
Research Funding - Lilly (Inst); Servier/Pfizer (Inst)
 
Massimo Aglietta
Research Funding - AstraZeneca; PharmaMar
 
Pilar Garcia-Alfonso
Consulting or Advisory Role - Amgen; Merck Serono; Pierre Fabre; SERVIER
Speakers' Bureau - Amgen; Merck Serono; Pierre Fabre; Sanofi; SERVIER
 
Bart Neyns
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
 
Fabio Gelsomino
Consulting or Advisory Role - Amgen; Merck
Speakers' Bureau - Bristol-Myers Squibb; Lilly O.; SERVIER
 
Dana Backlund Cardin
Honoraria - OncLive/MJH Life Sciences
Consulting or Advisory Role - Clarivate; the KOL Connection Ltd
Research Funding - Array BioPharma (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Elicio Therapeutics (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); XBiotech (Inst)
 
Tomislav Dragovich
Research Funding - ARMO BioSciences; Berg Pharma; Bristol-Myers Squibb (Inst); Halozyme (Inst); HolyStone Therapeutics (Inst); Kyowa Hakko Kirin; Medivir; Novocure (Inst); Rgenix
 
Usman Shah
No Relationships to Disclose
 
Stephen M. McCraith
Employment - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - RJSBiologics, LLC
 
Abigail Wang
Employment - Bristol-Myers Squibb
 
Ming Lei
Employment - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Jin Yao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Lixian Jin
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene
 
Sara Lonardi
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Lilly; Merck Serono; Mirati Therapeutics; MSD; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)